Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a ...

Cilta-cel plus daratumumab shows significant efficacy in multiple myeloma, offering prolonged progression-free survival and sustained MRD negativity, especially in high-risk patients. Acalabrutinib ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In this special crossover episode of ...

The latest update is out from Oncopeptides AB ( (SE:ONCO) ).

New research across a broad range of hematologic malignancies to be featured during the meeting, including presentations for investigational assets zilovertamab vedotin and nemtabrutinib RAHWAY, N.J.- ...

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through ...

Despite an 8% sales decline, Ashland Inc (ASH) maintained strong margins and achieved strategic gains in Life Sciences and ...